US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Niagen Bioscience

3.21

0.0000

Post-market: 3.210.00000.00%19:30 EDT

Volume:415.75K

Turnover:1.34M

Market Cap:255.66M

PE:16.88

High:3.28

Open:3.21

Low:3.19

Close:3.21

52wk High:10.52

52wk Low:2.87

Shares:79.64M

Float Shares:55.82M

Volume Ratio:0.76

T/O Rate:0.74%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.1901

EPS(LYR):0.2000

ROE:21.80%

ROA:5.44%

PB:3.10

PE(LYR):16.05

Loading ...

Overview Company News Filings

Niagen Bioscience Inc. Publishes Investor Presentation on NAD+ and Healthy Aging Strategy

Niagen Bioscience sees FY26 revenue up 10%-15%, implying $142.3M-$148.8M

Niagen Bioscience up 39% at $6.88 after Q4 results and guidance

Niagen Bioscience Q4 net sales rise

Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion

Benzinga Earnings

Niagen Bioscience Q4 EPS $0.05 Beats $0.02 Estimate, Sales $33.839M Beat $31.705M Estimate

Benzinga Earnings

Niagen Bioscience posts FY 2025 net income up 2.0x to USD 17.4 million

BRIEF-Niagen Bioscience Inc Q4 Sales USD 33.839 Million Vs. IBES Estimate USD 31.7 Million

Niagen Bioscience Inc Outlook FY Revenue Growth 10-15%

THOMSON REUTERS

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 Million, 103% Net Income Increase to $17.4 Million or $0.22 Basic EPS in 2025

THOMSON REUTERS

Niagen Bioscience Sells ChromaDex Reference Standards Business to LGC for Cash

Niagen Bioscience to Streamline and Focus Its Operations With the Sale of Chromadex Reference Standards Business to Lgc in All-Cash Transaction

THOMSON REUTERS

Niagen Bioscience Inc - Sells Chromadex Business to Lgc in All-Cash Deal

THOMSON REUTERS

BRIEF-Niagen Bioscience Secures New U.S. Patent For Nicotinamide Riboside

Niagen Bioscience Inc - Secures New U.S. Patent for Intravenous and Injection Formulations & Methods of Use for Nicotinamide Riboside

THOMSON REUTERS

Niagen Bioscience Wins New U.S. Patent for IV and Injectable Nicotinamide Riboside Formulations

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/NAGE/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NAGE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","market":"US","secType":"STK","nameCN":"Niagen Bioscience","latestPrice":3.21,"timestamp":1787601600000,"preClose":3.21,"halted":0,"volume":415746,"hourTrading":{"tag":"盘后","latestPrice":3.21,"preClose":3.21,"latestTime":"19:30 EDT","volume":1678,"amount":5386.9897851999995,"timestamp":1787614203352,"change":0,"changeRate":0,"amplitude":0.018692},"delay":0,"changeRate":0,"floatShares":55819168,"shares":79644327,"eps":0.190148,"marketStatus":"Post-Mkt","change":0,"latestTime":"08-24 19:48:29 EDT","open":3.21,"high":3.28,"low":3.19,"amount":1340921.0811258,"amplitude":0.028037,"askPrice":3.27,"askSize":1000,"bidPrice":2.89,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.190148,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":3.21,"preHourTrading":{"tag":"盘前","latestPrice":3.23,"preClose":3.21,"latestTime":"09:12 EDT","volume":5796,"amount":18438.6681612,"timestamp":1787577120251,"change":0.02,"changeRate":0.006231,"amplitude":0.149533},"postHourTrading":{"tag":"盘后","latestPrice":3.21,"preClose":3.21,"latestTime":"19:30 EDT","volume":1678,"amount":5386.9897851999995,"timestamp":1787614203352,"change":0,"changeRate":0,"amplitude":0.018692},"volumeRatio":0.756049,"impliedVol":0.8647,"impliedVolPercentile":0.1912},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","floatShares":55819168,"roa":"5.44%","roe":"21.80%","lyrEps":0.2,"volumeRatio":0.756049,"shares":79644327,"dividePrice":0,"high":3.28,"amplitude":0.028037,"preClose":3.21,"low":3.19,"week52Low":2.87,"pbRate":"3.10","psRate":"1.98","week52High":10.52,"institutionHeld":0,"latestPrice":3.21,"committee":-0.818182,"eps":0.190148,"divideRate":0,"volume":415746,"delay":0,"ttmEps":0.190148,"open":3.21,"prevYearClose":6.36,"prevWeekClose":3.21,"prevMonthClose":3.4,"prevQuarterClose":3.19,"fiveDayClose":3.04,"twentyDayClose":3.23,"sixtyDayClose":3.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NAGE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"NAGE","fiscalQuarterEnding":"2026/06","expectedEps":0.01,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"post","actualEps":0.01},{"market":"US","date":"2026-05-06","symbol":"NAGE","fiscalQuarterEnding":"2026/03","expectedEps":0.06,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778040000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2026-03-04","symbol":"NAGE","fiscalQuarterEnding":"2025/12","expectedEps":0.02,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772600400000,"reportTimeType":"post","actualEps":0.03},{"market":"US","date":"2025-11-04","symbol":"NAGE","fiscalQuarterEnding":"2025/09","expectedEps":0.02,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":0.05},{"market":"US","date":"2025-08-06","symbol":"NAGE","fiscalQuarterEnding":"2025/06","expectedEps":0.02,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":0.04}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NAGE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NAGE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1783396800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NAGE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NAGE","date":"2026-08-21","current":17.118245,"percent":0.148876,"low":13.660897,"twenty":18.243689,"median":26.266446,"eighty":56.409541,"high":80.643552,"avg":35.623148,"sd":19.714561,"marketCap":249772956},"quantilePoints":[{"date":"2025-03-21","current":69.624479,"twenty":69.806742,"median":70.080136,"eighty":70.353531,"marketCap":595289295},{"date":"2025-03-28","current":67.346191,"twenty":68.676711,"median":69.624479,"eighty":70.371757,"marketCap":575809933},{"date":"2025-04-04","current":60.420196,"twenty":62.662031,"median":67.938546,"eighty":69.697384,"marketCap":516592673},{"date":"2025-04-11","current":51.67157,"twenty":54.861173,"median":62.880747,"eighty":69.551574,"marketCap":441791924},{"date":"2025-04-17","current":59.600012,"twenty":54.815607,"median":61.696037,"eighty":69.259953,"marketCap":509580103},{"date":"2025-04-25","current":67.255059,"twenty":55.043436,"median":62.151694,"eighty":68.530901,"marketCap":575030758},{"date":"2025-05-02","current":68.895427,"twenty":55.954751,"median":62.880747,"eighty":69.442216,"marketCap":589055899},{"date":"2025-05-09","current":51.710369,"twenty":55.954751,"median":65.022337,"eighty":70.535794,"marketCap":729374756},{"date":"2025-05-16","current":58.761783,"twenty":54.815607,"median":62.789615,"eighty":69.71561,"marketCap":828834951},{"date":"2025-05-23","current":56.859021,"twenty":55.043436,"median":61.650471,"eighty":69.624479,"marketCap":801996485},{"date":"2025-05-30","current":60.552618,"twenty":55.242319,"median":61.364091,"eighty":69.478669,"marketCap":854094682},{"date":"2025-06-06","current":64.414107,"twenty":55.822209,"median":61.604905,"eighty":69.296406,"marketCap":908560979},{"date":"2025-06-13","current":79.132535,"twenty":56.409541,"median":62.698483,"eighty":70.55402,"marketCap":1116164400},{"date":"2025-06-20","current":77.117845,"twenty":56.623974,"median":63.647427,"eighty":71.912091,"marketCap":1087747202},{"date":"2025-06-27","current":77.341699,"twenty":56.791865,"median":65.523561,"eighty":75.181504,"marketCap":1090904668},{"date":"2025-07-03","current":71.129739,"twenty":57.426855,"median":65.645306,"eighty":75.483707,"marketCap":1003284974},{"date":"2025-07-11","current":65.981088,"twenty":58.471876,"median":66.48476,"eighty":75.192697,"marketCap":930663244},{"date":"2025-07-18","current":57.950311,"twenty":58.471876,"median":65.645306,"eighty":75.114348,"marketCap":817389135},{"date":"2025-07-25","current":51.87826,"twenty":56.758286,"median":65.022337,"eighty":74.190401,"marketCap":731742856},{"date":"2025-08-01","current":52.325969,"twenty":55.224884,"median":64.358143,"eighty":72.732275,"marketCap":738057789},{"date":"2025-08-08","current":43.320593,"twenty":54.318273,"median":62.947882,"eighty":72.15947,"marketCap":768030786},{"date":"2025-08-15","current":43.771379,"twenty":53.985743,"median":62.607352,"eighty":71.628921,"marketCap":776022782},{"date":"2025-08-22","current":44.041851,"twenty":52.415511,"median":61.650471,"eighty":71.37484,"marketCap":780817979},{"date":"2025-08-29","current":44.267244,"twenty":51.68709,"median":61.280145,"eighty":71.129739,"marketCap":784813977},{"date":"2025-09-05","current":42.013311,"twenty":50.71606,"median":60.552618,"eighty":71.083855,"marketCap":744853999},{"date":"2025-09-12","current":43.365671,"twenty":45.745824,"median":60.318517,"eighty":70.845641,"marketCap":768829986},{"date":"2025-09-19","current":45.709762,"twenty":45.222912,"median":59.50888,"eighty":70.6087,"marketCap":810388363},{"date":"2025-09-26","current":42.419019,"twenty":45.024566,"median":58.520194,"eighty":70.371757,"marketCap":752046795},{"date":"2025-10-03","current":33.268051,"twenty":44.46559,"median":56.887002,"eighty":69.697384,"marketCap":589809282},{"date":"2025-10-10","current":34.079467,"twenty":44.02382,"median":56.607185,"eighty":69.623328,"marketCap":604194874},{"date":"2025-10-17","current":33.448366,"twenty":43.66319,"median":55.29204,"eighty":69.583421,"marketCap":593006080},{"date":"2025-10-24","current":33.448366,"twenty":43.41075,"median":54.929521,"eighty":69.405763,"marketCap":593006080},{"date":"2025-10-31","current":32.050928,"twenty":43.28453,"median":54.228731,"eighty":69.187048,"marketCap":568230894},{"date":"2025-11-07","current":25.87441,"twenty":42.455082,"median":54.050915,"eighty":68.822522,"marketCap":528588317},{"date":"2025-11-14","current":27.403352,"twenty":42.022327,"median":53.333314,"eighty":68.390298,"marketCap":559823081},{"date":"2025-11-21","current":26.30565,"twenty":34.151593,"median":52.437896,"eighty":67.731548,"marketCap":537398122},{"date":"2025-11-28","current":26.540872,"twenty":33.854074,"median":52.018169,"eighty":67.346191,"marketCap":542203471},{"date":"2025-12-05","current":26.266446,"twenty":33.628681,"median":51.67157,"eighty":67.255059,"marketCap":536597231},{"date":"2025-12-12","current":25.992021,"twenty":33.448366,"median":50.903505,"eighty":67.255059,"marketCap":530990991},{"date":"2025-12-19","current":25.482373,"twenty":32.772186,"median":49.393282,"eighty":66.988433,"marketCap":520579403},{"date":"2025-12-26","current":25.913613,"twenty":32.474667,"median":46.160548,"eighty":66.182557,"marketCap":529389208},{"date":"2026-01-02","current":24.933522,"twenty":30.002996,"median":45.709762,"eighty":65.94751,"marketCap":509366924},{"date":"2026-01-09","current":25.717595,"twenty":27.520963,"median":45.43929,"eighty":65.757233,"marketCap":525384751},{"date":"2026-01-16","current":24.737504,"twenty":27.019156,"median":45.168818,"eighty":65.594939,"marketCap":505362467},{"date":"2026-01-23","current":24.619893,"twenty":26.909386,"median":44.627874,"eighty":65.546241,"marketCap":502959792},{"date":"2026-01-30","current":23.482987,"twenty":26.540872,"median":44.492638,"eighty":65.122582,"marketCap":479733942},{"date":"2026-02-06","current":20.111473,"twenty":26.282128,"median":44.267244,"eighty":64.478311,"marketCap":410857283},{"date":"2026-02-13","current":19.954658,"twenty":25.944976,"median":44.008043,"eighty":64.391721,"marketCap":407653717},{"date":"2026-02-20","current":19.366604,"twenty":25.843047,"median":43.816458,"eighty":64.134289,"marketCap":395640346},{"date":"2026-02-27","current":20.307491,"twenty":25.623506,"median":43.591065,"eighty":63.1941,"marketCap":414861740},{"date":"2026-03-06","current":23.545172,"twenty":25.529418,"median":43.41075,"eighty":62.988163,"marketCap":409262188},{"date":"2026-03-13","current":22.252496,"twenty":25.411807,"median":43.320593,"eighty":62.862521,"marketCap":386792892},{"date":"2026-03-20","current":21.88316,"twenty":25.058974,"median":43.095199,"eighty":62.753162,"marketCap":380373093},{"date":"2026-03-27","current":20.636651,"twenty":24.761026,"median":42.599334,"eighty":62.487416,"marketCap":358706271},{"date":"2026-04-02","current":20.867486,"twenty":24.619893,"median":42.419019,"eighty":62.007672,"marketCap":362718645},{"date":"2026-04-10","current":20.682818,"twenty":24.345467,"median":42.035851,"eighty":61.696037,"marketCap":359508746},{"date":"2026-04-17","current":21.836993,"twenty":23.875024,"median":35.567063,"eighty":61.604905,"marketCap":379570618},{"date":"2026-04-24","current":21.836993,"twenty":23.545172,"median":34.102007,"eighty":61.448036,"marketCap":379570618},{"date":"2026-05-01","current":21.836993,"twenty":23.175836,"median":33.854074,"eighty":61.280145,"marketCap":379570618},{"date":"2026-05-08","current":18.041368,"twenty":22.760333,"median":33.696298,"eighty":61.168218,"marketCap":336236974},{"date":"2026-05-15","current":16.273169,"twenty":22.34483,"median":33.493445,"eighty":60.552618,"marketCap":303283042},{"date":"2026-05-22","current":16.230344,"twenty":22.248072,"median":33.448366,"eighty":60.552618,"marketCap":302484929},{"date":"2026-05-29","current":16.444465,"twenty":22.012428,"median":33.155355,"eighty":60.44668,"marketCap":306475495},{"date":"2026-06-05","current":14.988445,"twenty":21.873927,"median":32.772186,"eighty":60.257509,"marketCap":279339644},{"date":"2026-06-12","current":14.688676,"twenty":21.735571,"median":32.546792,"eighty":59.723377,"marketCap":273752851},{"date":"2026-06-18","current":14.431731,"twenty":21.468256,"median":32.208703,"eighty":59.545333,"marketCap":268964171},{"date":"2026-06-26","current":14.174786,"twenty":20.98752,"median":28.148222,"eighty":59.396403,"marketCap":264175492},{"date":"2026-07-02","current":14.260435,"twenty":20.867486,"median":27.834592,"eighty":59.097565,"marketCap":265771718},{"date":"2026-07-10","current":14.945621,"twenty":20.636651,"median":27.324945,"eighty":58.568512,"marketCap":278541531},{"date":"2026-07-17","current":14.560203,"twenty":20.370149,"median":27.050519,"eighty":58.147287,"marketCap":271358511},{"date":"2026-07-24","current":13.660897,"twenty":20.127155,"median":26.95251,"eighty":57.524987,"marketCap":254598133},{"date":"2026-07-31","current":14.21761,"twenty":20.033066,"median":26.893705,"eighty":56.881406,"marketCap":264973605},{"date":"2026-08-07","current":15.07415,"twenty":19.767151,"median":26.540872,"eighty":56.825443,"marketCap":241050726},{"date":"2026-08-14","current":15.123736,"twenty":19.424638,"median":26.403659,"eighty":56.657552,"marketCap":241843656},{"date":"2026-08-21","current":15.619596,"twenty":18.243689,"median":26.266446,"eighty":56.409541,"marketCap":249772956}],"updateTime":1787586724074},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NAGE\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2617629245","title":"Niagen Bioscience Inc. Publishes Investor Presentation on NAD+ and Healthy Aging Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2617629245","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617629245?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:29","pubTimestamp":1772663384,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. released an investor presentation outlining its NAD+ product portfolio, including the Tru Niagen supplement and the Niagen Plus lineup for IV and injectable formats. The company reported FY 2025 revenue of $129.4 million, net income of $17.4 million, and cash of $64.8 million with no debt. The presentation also highlighted Niagen IV and injectables initiatives, including an NAD+ test kit and a targeted at-home injectable product launch in the first half of 2026, and noted early adoption metrics since the August 2024 launch. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news bri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL1bj7jx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617649875","title":"Niagen Bioscience sees FY26 revenue up 10%-15%, implying $142.3M-$148.8M","url":"https://stock-news.laohu8.com/highlight/detail?id=2617649875","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617649875?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:45","pubTimestamp":1772660741,"startTime":"0","endTime":"0","summary":"Consensus $152.9M. Sees FY26 gross margin with “slight improvement year-over-year, driven by improvements in inventory cost and product mix.” Publi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-sees-fy26-revenue-up-10-15-implying-142-3m-148-8m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-sees-fy26-revenue-up-10-15-implying-142-3m-148-8m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617646085","title":"Niagen Bioscience up 39% at $6.88 after Q4 results and guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2617646085","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617646085?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:45","pubTimestamp":1772660721,"startTime":"0","endTime":"0","summary":"16:41 EST Niagen Bioscience (NAGE) up 39% at $6.88 after Q4 results and guidance Published first on TheFly – the ultimate source for real-time, mar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-up-39-at-6-88-after-q4-results-and-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-up-39-at-6-88-after-q4-results-and-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617569526","title":"Niagen Bioscience Q4 net sales rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569526","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569526?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:12","pubTimestamp":1772658744,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Q4 net sales riseOverviewBioscience company's Q4 net sales rose 16%, beating analyst expectationsNet income for Q4 declined due to higher operating expensesGross margin improved 160 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL1N3ZS1B7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203347892.USD","LU0203345920.USD","CMI","NAGE","BK4585","LU0154245756.USD","BK4183","BK4533","BK4149","LU0154245673.USD","BK4121","BK4588","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617566094","title":"Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566094","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566094?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:06","pubTimestamp":1772658381,"startTime":"0","endTime":"0","summary":"NAD+ company Niagen Bioscience doubles profits in 2025, eyes acquisitions and new markets as the longevity market picks up momentum.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/03/51050507/niagen-bioscience-doubles-annual-profit-ceo-signals-acquisition-hunt-and-glp-1-style-expansion","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLP","BK4144","BK4183","BK4121","BK4590","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617667425","title":"Niagen Bioscience Q4 EPS $0.05 Beats $0.02 Estimate, Sales $33.839M Beat $31.705M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617667425","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617667425?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:03","pubTimestamp":1772658193,"startTime":"0","endTime":"0","summary":"Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 127.27 percent. This is a 44.44 percent decrease over earnings of $0.09 per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51050229/niagen-bioscience-q4-eps-0-05-beats-0-02-estimate-sales-33-839m-beat-31-705m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Niagen Bioscience Q4 EPS $0.05 Beats $0.02 Estimate, Sales $33.839M Beat $31.705M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617456644","title":"Niagen Bioscience posts FY 2025 net income up 2.0x to USD 17.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617456644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617456644?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:03","pubTimestamp":1772658183,"startTime":"0","endTime":"0","summary":"Niagen Bioscience posts FY 2025 net income up 2.0x to USD 17.4 million               Niagen Bio reported FY 2025 net sales of USD 129.4 million (+30.0% YoY) and net income of USD 17.4 million (2.0x Yo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL4hvxy9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617566458","title":"BRIEF-Niagen Bioscience Inc Q4 Sales USD 33.839 Million Vs. IBES Estimate USD 31.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566458","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566458?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:02","pubTimestamp":1772658166,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Inc Q4 Sales USD 33.839 Million Vs. IBES Estimate USD 31.7 Million\n\n\nMar 04 (Reuters) - Niagen Bioscience Inc Q4 net income USD 4.132 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nPLXE0E1D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617569980","title":"Niagen Bioscience Inc Outlook FY Revenue Growth 10-15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569980?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:02","pubTimestamp":1772658121,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nPLXE0E1D6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617661575","title":"Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 Million, 103% Net Income Increase to $17.4 Million or $0.22 Basic EPS in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2617661575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617661575?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:02","pubTimestamp":1772658120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA9TSH7K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","NAGE","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614045061","title":"Niagen Bioscience Sells ChromaDex Reference Standards Business to LGC for Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045061","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045061?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:07","pubTimestamp":1772107664,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. said it has sold its ChromaDex Reference Standards business to LGC in an all-cash transaction, effective Feb. 24, 2026. The company said the divestiture is intended to streamline operations and sharpen its focus on NAD+ science, intellectual property, and commercial growth in the longevity market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL5PF42V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614045990","title":"Niagen Bioscience to Streamline and Focus Its Operations With the Sale of Chromadex Reference Standards Business to Lgc in All-Cash Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045990","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045990?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:02","pubTimestamp":1772107320,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA1LRJV8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614004512","title":"Niagen Bioscience Inc - Sells Chromadex Business to Lgc in All-Cash Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2614004512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614004512?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:02","pubTimestamp":1772107320,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA1LRJV8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAGE","BK4121","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614904080","title":"BRIEF-Niagen Bioscience Secures New U.S. Patent For Nicotinamide Riboside","url":"https://stock-news.laohu8.com/highlight/detail?id=2614904080","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614904080?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:41","pubTimestamp":1772026883,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Secures New U.S. Patent For Nicotinamide RibosideFeb 25 (Reuters) - Niagen Bioscience Inc NAGE.O:NIAGEN BIOSCIENCE INC - SECURES NEW U.S. PATENT FOR INTRAVENOUS AND INJECTION F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL11U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614080391","title":"Niagen Bioscience Inc - Secures New U.S. Patent for Intravenous and Injection Formulations & Methods of Use for Nicotinamide Riboside","url":"https://stock-news.laohu8.com/highlight/detail?id=2614080391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614080391?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:36","pubTimestamp":1772026594,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL11U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","NAGE","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614080857","title":"Niagen Bioscience Wins New U.S. Patent for IV and Injectable Nicotinamide Riboside Formulations","url":"https://stock-news.laohu8.com/highlight/detail?id=2614080857","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614080857?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:32","pubTimestamp":1772026356,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. said it has been granted U.S. Patent No. 12,558,367, covering methods of use of nicotinamide riboside  and derivatives in intravenous and injectable formulations. The company said the patent adds protection for aqueous formulations, multiple administration routes and parameters, select NR salt forms, and combination use with other NAD+ precursors, with expected protection through 2044.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire  on February 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL2w9L9t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":116,"code":"91000000","status":"200"}]}}